In a welcome move, Axsome Therapeutics saw its Relative Strength Rating improve from 70 to 79 on Tuesday.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks tend to have an RS Rating north of 80 as they launch their biggest climbs. See if Axsome Therapeutics can continue to rebound and clear that threshold.
Axsome Therapeutics is not currently near a potential buy zone. See if the stock goes on to build a base that could kick off a new climb.
The company posted 0% earnings growth in the latest quarterly report, while sales growth came in at 62%.
Axsome Therapeutics earns the No. 100 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Anbio Biotechnology are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
